Zacks Research Issues Negative Outlook for Medifast Earnings

Medifast, Inc. (NYSE:MED) – Research analysts at Zacks Research cut their Q2 2025 EPS estimates for Medifast in a note issued to investors on Monday, March 10th. Zacks Research analyst R. Department now forecasts that the specialty retailer will post earnings per share of $0.24 for the quarter, down from their previous forecast of $0.29. The consensus estimate for Medifast’s current full-year earnings is $0.51 per share. Zacks Research also issued estimates for Medifast’s Q3 2025 earnings at $0.33 EPS, Q1 2026 earnings at $0.32 EPS, Q2 2026 earnings at $0.32 EPS, FY2026 earnings at $1.52 EPS and FY2027 earnings at $2.08 EPS.

Medifast (NYSE:MED) last issued its quarterly earnings results on Tuesday, February 18th. The specialty retailer reported $0.10 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.16) by $0.26. The company had revenue of $119.00 million for the quarter, compared to the consensus estimate of $114.25 million. Medifast had a return on equity of 10.64% and a net margin of 0.35%.

Separately, DA Davidson cut their price target on shares of Medifast from $17.00 to $16.50 and set a “neutral” rating on the stock in a research note on Wednesday, February 19th.

Medifast Price Performance

MED opened at $14.32 on Wednesday. Medifast has a 12 month low of $13.57 and a 12 month high of $39.14. The stock has a market capitalization of $156.63 million, a price-to-earnings ratio of 79.56 and a beta of 1.13. The business has a fifty day moving average price of $15.39 and a 200 day moving average price of $17.48.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of MED. Two Sigma Advisers LP boosted its stake in shares of Medifast by 86.0% during the fourth quarter. Two Sigma Advisers LP now owns 216,000 shares of the specialty retailer’s stock valued at $3,806,000 after acquiring an additional 99,900 shares during the last quarter. Two Sigma Investments LP raised its stake in shares of Medifast by 11.4% in the 4th quarter. Two Sigma Investments LP now owns 232,069 shares of the specialty retailer’s stock valued at $4,089,000 after acquiring an additional 23,822 shares during the period. State of Wyoming raised its stake in shares of Medifast by 286.1% in the 4th quarter. State of Wyoming now owns 11,312 shares of the specialty retailer’s stock valued at $199,000 after acquiring an additional 8,382 shares during the period. Deutsche Bank AG increased its stake in Medifast by 10.4% during the 4th quarter. Deutsche Bank AG now owns 29,553 shares of the specialty retailer’s stock worth $521,000 after buying an additional 2,787 shares during the period. Finally, Bridgeway Capital Management LLC purchased a new stake in Medifast during the 4th quarter worth $352,000. Institutional investors and hedge funds own 95.51% of the company’s stock.

Medifast Company Profile

Medifast, Inc, through its subsidiaries, engages in the manufacture and sale of weight loss, weight management, and healthy living products in the United States and the Asia-Pacific. It offers bars, puffs, cereal, crunchers, drinks, hearty choices, oatmeal, pancakes, pudding, soft serve, shakes, smoothies, soft bakes, and soups under the OPTAVIA, OPTAVIA ACTIVE, and Optimal Health brand names.